Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- W. Marc Hertz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- -0.66
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -6.26
Financials
Revenue
$0.00-100.0%Net Income
$-1.64MEBITDA
$-1.65MFree Cash Flow
$-1.45MEPS (diluted)
$-0.91Shares Outstanding (diluted)
1.80M+202475.9%Operating Expenses
$1.65MCash & Debt
$10.95MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-11.96M | $-121.80 |
| 2024 | $0.00 | $-8.21M | $0.33 |
| 2023 | $0.00 | $-13.04M | $-140450.24 |
| 2022 | $0.00 | $-3.22M | $-47135.48 |
| 2021 | $0.00 | $-1.56M | $-2827.16 |
| 2020 | $100.0K | $-2.53M | $-4693.64 |
| 2019 | $0.00 | $-3.46M | $-660968.00 |
| 2018 | $0.00 | $-4.31M | $-822780.00 |
Valuation
GRIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·10d ago·Neutral
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translating immune biology and clinical signals into novel therapeutic approaches for IPF
View source ↗ - Newszacks.com·24d ago·Positive
GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock? GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection
View source ↗ - Newsglobenewswire.com·42d ago·Negative
GRI Bio Featured in "Why Now" On-Demand Video Webcast Video webcast now available here
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been s…
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.84 per share
Typical surprise -22.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.91 vs $-1.19beat
- Wed, May 13$-1.61 vs $-0.91miss
- Fri, Mar 13$-13.25 vs $-29.27beat
- Fri, Nov 14$-35.85 vs $-29.26miss
- Thu, Aug 14$-36.69 vs $-36.69beat
- Tue, Aug 12$-162.40 vs $-1.31miss
Estimates and results for GRI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GRI officers and directors.
No open-market trades in the recent filings. All 25 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
25 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GRI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.